Self‐Reported Pharmacogenetic Medication Use in the Our Future Health Cohort
Clinical and Translational Science · 2026
DOI: 10.1111/cts.70471 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Science, 2026. Verfasst von Padraig Dixon und 4 weiteren Autor:innen. Beteiligte Einrichtung: Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK. Hauptthemen laut MEDLINE: Self Report, Pharmacogenetics. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The aim of this study was to describe self‐reported use of medications with established pharmacogenetic guidance in the Our Future Health (OFH) cohort. We examined four key pharmacogenes— CYP2C19, CYP2C9, CYP2D6, and SLCO1B1 —and medications supported by strong evidence for clinical actionability according to the Clinical Pharmacogenetics Implementation Consortium (CPIC). Self‐reported medication use was summarized, concurrent use assessed, and findings stratified by age, sex, and ethnicity. We studied these data in 1.78 million OFH participants included in the June 2025 release. The cohort was 57.3% female, aged 18–95 years (mean 53.1 years), with 90.2% self‐identifying as “White.” Eighteen medication groups were explicitly listed in the baseline questionnaire, enabling identification of exposure at group level rather than for individual drugs. Medication groups with pharmacogenetic relevance included antidepressants (selective serotonin reuptake inhibitors and tricyclics), statins, proton pump inhibitors, ibuprofen, opioids, clopidogrel, and warfarin. Overall, 25.2% of participants ( N = 449,641) reported use of at least one such group. These users tended to be older, more frequently female, and reported more comorbidities than non‐users. Concurrent exposure to two or more pharmacogenetically actionable medications metabolized by different genes was common, occurring in 37% of users. A substantial proportion of the OFH cohort therefore reported exposure to medications with pharmacogenetic guidance. Use was observed across all ages, with prevalence increasing with age. With continued expansion of the cohort and future linkage to prescribing records, OFH will provide a critical resource for population‐scale pharmacogenetic research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
- Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University, NHS Foundation Trust, Manchester, UK.
- Division of Evolution and Genomic Sciences, School of Biological Sciences, University of Manchester, Manchester, UK.
ORCID-Profile: Padraig Dixon, William G Newman, Videha Sharma, John H McDermott
Zitieren
APA
Dixon, P., Newman, W. G., Sharma, V., McDermott, J. H., & Wright Drakesmith, C. (2026). Self‐Reported Pharmacogenetic Medication Use in the Our Future Health Cohort. Clinical and Translational Science. https://doi.org/10.1111/cts.70471
Vancouver
Dixon P, Newman WG, Sharma V, McDermott JH, Wright Drakesmith C. Self‐Reported Pharmacogenetic Medication Use in the Our Future Health Cohort. Clinical and Translational Science. 2026. doi:10.1111/cts.70471
BibTeX
@article{Dixon2026,
author = {Dixon, Padraig and Newman, William G and Sharma, Videha and McDermott, John H and Wright Drakesmith, Cynthia},
title = {Self‐Reported Pharmacogenetic Medication Use in the Our Future Health Cohort},
journal = {Clinical and Translational Science},
year = {2026},
doi = {10.1111/cts.70471}
}
EUVIMED